

# ErbB-4 (2Q322): sc-71071

## BACKGROUND

The EGF receptor family comprises several related receptor tyrosine kinases that are frequently overexpressed in a variety of carcinomas. Members of this receptor family include EGFR (HER1), Neu (ErbB-2, HER2), ErbB-3 (HER3) and ErbB-4 (HER4), which form either homodimers or heterodimers upon ligand binding. The gene encoding ErbB-4 is expressed as a full length protein, which produces a short membrane-anchored cytoplasmic domain fragment and a long ectodomain fragment. The short fragment is heavily tyrosine phosphorylated and possesses tyrosine kinase catalytic activity toward an exogenous substrate. Proteolytic cleavage of ErbB-4 is promoted by the binding of heregulin. ErbB-4 is involved in cell proliferation and differentiation and its expression is highest in breast carcinoma cell lines, normal skeletal muscle, heart, pituitary, brain and cerebellum.

## CHROMOSOMAL LOCATION

Genetic locus: ERBB4 (human) mapping to 2q34; Erbb4 (mouse) mapping to 1 C3.

## SOURCE

ErbB-4 (2Q322) is a mouse monoclonal antibody raised against amino acids 1249-1264 of ErbB-4 of mouse origin.

## PRODUCT

Each vial contains 200 µg IgG<sub>2b</sub> kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

ErbB-4 (2Q322) is available conjugated to HRP (sc-71071 HRP), 200 µg/ml, for WB, IHC(P) and ELISA.

## STORAGE

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## APPLICATIONS

ErbB-4 (2Q322) is recommended for detection of ErbB-4 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500).

Suitable for use as control antibody for ErbB-4 siRNA (h): sc-35329, ErbB-4 siRNA (m): sc-35330, ErbB-4 shRNA Plasmid (h): sc-35329-SH, ErbB-4 shRNA Plasmid (m): sc-35330-SH, ErbB-4 shRNA (h) Lentiviral Particles: sc-35329-V and ErbB-4 shRNA (m) Lentiviral Particles: sc-35330-V.

Molecular Weight of ErbB-4 precursor: 180 kDa.


Molecular Weight of ErbB-4 cleaved forms: 80/120 kDa.

Positive Controls: F9 cell lysate: sc-2245, mouse brain extract: sc-2253 or human ErbB-4 transfected NIH/3T3 whole cell lysate.


## RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use m-IgGκ BP-FITC: sc-516140 or m-IgGκ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz® Mounting Medium: sc-24941 or UltraCruz® Hard-set Mounting Medium: sc-359850. 4) Immunohistochemistry: use m-IgGκ BP-HRP: sc-516102 with DAB, 50X: sc-24982 and Immunohistomount: sc-45086, or Organo/Limonene Mount: sc-45087.

## DATA



ErbB-4 (2Q322): sc-71071. Western blot analysis of ErbB-4 expression in human ErbB-4 transfected NIH/3T3 whole cell lysate.



ErbB-4 (2Q322): sc-71071. Western blot analysis of ErbB-4 expression in F9 whole cell lysate.

## SELECT PRODUCT CITATIONS

1. Leccia, F., et al. 2012. Cytometric and biochemical characterization of human breast cancer cells reveals heterogeneous myoepithelial phenotypes. *Cytometry A* 81: 960-972.
2. Bush, M.L., et al. 2012. Treatment of vestibular schwannoma cells with ErbB inhibitors. *Otol. Neurotol.* 33: 244-257.
3. Ni, H., et al. 2019. ErbB-4 acts as a suppressor in colitis and its associated carcinoma by negatively regulating cholesterol metabolism. *Carcinogenesis* 40: 680-686.
4. Qiao, X.Y., et al. 2023. Involvement of CXCL10 in neuronal damage under the condition of spinal cord injury and the potential therapeutic effect of Nrg1. *J. Integr. Neurosci.* 22: 96.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.

## PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) for detailed protocols and support products.



See **ErbB-4 (C-7): sc-8050** for ErbB-4 antibody conjugates, including AC, HRP, FITC, PE, and Alexa Fluor® 488, 546, 594, 647, 680 and 790.